ALPHARETTA, Ga., July 24, 2024 /PRNewswire/ — Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2024 on Wednesday, July 31 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day.
The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer.
To join the live conference call, dial 1-800-836-8184 in the United States. A simultaneous webcast of the call and a related presentation will be accessible via the Investors section of the Avanos Medical website, https://avanos.investorroom.com/.
A replay of the conference call will be available May 2 at noon ET by dialing 1-888-660-6345 in the United States and entering passcode 70891#. It will be available for one week. A replay of the webcast also will be accessible in the Investors section of the website, approximately one hour following the completion of the conference call.
About Avanos Medical
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today’s most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures, and markets its recognized brands globally and holds leading market positions in multiple product categories. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
SOURCE Avanos Medical
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq:…
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed”…
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined…
HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2024 December 27, 2024, 6.00 p.m. Safe Group announces…
GRANTS, NEW MEXICO, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright…
BOSTON, Dec. 27, 2024 /PRNewswire/ -- Judge Baker Children's Center d/b/a The Baker Center for…